Blincyto Blinatumomab 35 Mcg


Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers, that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated

Specification/Additional Details

  • 1mlx12.5 mcg
  • Injection
  • Blinatumomab



There are no reviews yet.

Be the first to review “Blincyto Blinatumomab 35 Mcg”

Your email address will not be published. Required fields are marked *

Shopping Cart
Open chat
Hey Patron, Medicines here are only delivered once you provide a Valid Prescription. Order Now!